SE8604007L - Vaccin och immunoanalyser for forvervat immunbristsyndrom (aids) - Google Patents

Vaccin och immunoanalyser for forvervat immunbristsyndrom (aids)

Info

Publication number
SE8604007L
SE8604007L SE8604007A SE8604007A SE8604007L SE 8604007 L SE8604007 L SE 8604007L SE 8604007 A SE8604007 A SE 8604007A SE 8604007 A SE8604007 A SE 8604007A SE 8604007 L SE8604007 L SE 8604007L
Authority
SE
Sweden
Prior art keywords
immuno
syndrome
lav
vaccin
cancel
Prior art date
Application number
SE8604007A
Other languages
English (en)
Swedish (sv)
Other versions
SE8604007D0 (sv
Inventor
S-L Hu
L Madisen
A F Purchio
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of SE8604007D0 publication Critical patent/SE8604007D0/xx
Publication of SE8604007L publication Critical patent/SE8604007L/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SE8604007A 1985-09-25 1986-09-23 Vaccin och immunoanalyser for forvervat immunbristsyndrom (aids) SE8604007L (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77990985A 1985-09-25 1985-09-25
US84298486A 1986-03-27 1986-03-27
US90521786A 1986-09-09 1986-09-09

Publications (2)

Publication Number Publication Date
SE8604007D0 SE8604007D0 (sv) 1986-09-23
SE8604007L true SE8604007L (sv) 1987-03-26

Family

ID=27419757

Family Applications (4)

Application Number Title Priority Date Filing Date
SE8604007A SE8604007L (sv) 1985-09-25 1986-09-23 Vaccin och immunoanalyser for forvervat immunbristsyndrom (aids)
SE9102974A SE9102974L (sv) 1985-09-25 1991-10-14 Adenovira och vaerd till anvaendning foer framstaellning av hiv-proteiner och peptider
SE9102975A SE9102975L (sv) 1985-09-25 1991-10-14 Bakterofag och vaerd till anvaendning foer framstaellning av hiv-proteiner och peptider
SE9102976A SE9102976L (sv) 1985-09-25 1991-10-14 Hybrid dna vektorer, encelliga organismer och bakterier till anvaendning foer produktion av hiv-proteiner och peptider

Family Applications After (3)

Application Number Title Priority Date Filing Date
SE9102974A SE9102974L (sv) 1985-09-25 1991-10-14 Adenovira och vaerd till anvaendning foer framstaellning av hiv-proteiner och peptider
SE9102975A SE9102975L (sv) 1985-09-25 1991-10-14 Bakterofag och vaerd till anvaendning foer framstaellning av hiv-proteiner och peptider
SE9102976A SE9102976L (sv) 1985-09-25 1991-10-14 Hybrid dna vektorer, encelliga organismer och bakterier till anvaendning foer produktion av hiv-proteiner och peptider

Country Status (22)

Country Link
CN (1) CN1020752C (enrdf_load_html_response)
AT (1) ATA256786A (enrdf_load_html_response)
CH (1) CH676247A5 (enrdf_load_html_response)
DE (1) DE3690508T1 (enrdf_load_html_response)
DK (1) DK455486A (enrdf_load_html_response)
ES (2) ES2002490A6 (enrdf_load_html_response)
FI (1) FI863848L (enrdf_load_html_response)
FR (1) FR2587720A2 (enrdf_load_html_response)
GB (1) GB2181435B (enrdf_load_html_response)
GR (1) GR862412B (enrdf_load_html_response)
HU (1) HU205780B (enrdf_load_html_response)
IE (1) IE59314B1 (enrdf_load_html_response)
IL (1) IL80073A (enrdf_load_html_response)
IT (1) IT1195829B (enrdf_load_html_response)
MY (1) MY103182A (enrdf_load_html_response)
NL (1) NL8602422A (enrdf_load_html_response)
NO (1) NO863803L (enrdf_load_html_response)
NZ (1) NZ217645A (enrdf_load_html_response)
PT (1) PT83434B (enrdf_load_html_response)
SE (4) SE8604007L (enrdf_load_html_response)
WO (1) WO1987002038A1 (enrdf_load_html_response)
YU (1) YU46753B (enrdf_load_html_response)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006099A1 (en) * 1985-04-08 1986-10-23 Genetic Systems Corporation EXPRESSION AND DIAGNOSTIC USE OF gag ENCODED PEPTIDES WHICH ARE IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES TO LAV
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
DE3750151T2 (de) * 1986-09-19 1994-12-01 Oncogen Verwendung von aktivierten T-Lymphozyten zur Vorbereitung einer pharmazeutischen Zusammensetzung zur Behandlung von AIDS.
IE872748L (en) * 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
JPS63258575A (ja) * 1986-12-15 1988-10-26 レプリゲン　コーポレーション 昆虫細胞中でつくられる組換えｈｉｖエンベロープタンパク
FR2610632B1 (fr) * 1987-02-11 1990-12-21 Pasteur Institut Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
ES2104556T3 (es) * 1987-01-16 1997-10-16 Pasteur Institut Peptidos que tienen propiedades inmunologicas de hiv-2.
US5681713A (en) * 1987-05-08 1997-10-28 Smithkline Beecham Corporation Expression of heterologous proteins in Drosophila cells
GB8714802D0 (en) * 1987-06-24 1987-07-29 Proteus Biotech Ltd Synthetic polypeptides
DE10399031I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
FR2620030B1 (fr) * 1987-09-07 1990-03-23 Transgene Sa Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
EP0343132B1 (en) * 1988-05-06 1994-08-17 Ferropas Ag Methods and systems for producing HIV antigens
US5043262A (en) * 1988-05-12 1991-08-27 Dana Farber Cancer Institute Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use
AP129A (en) * 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
WO1989012095A1 (en) * 1988-06-10 1989-12-14 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
EP0469089B1 (en) * 1989-04-18 1997-11-19 Applied Biotechnology, Inc. Generation of hybrid genes and proteins by virus-mediated recombination
DE69034052T2 (de) * 1989-06-01 2003-09-25 Applied Biotechnology, Inc. Rekombinante vectoren , die für selbstzusammengesetzte, defekte, sich nichtselbstvermehrende viruspartikel kodieren
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
FR2676068B1 (fr) * 1991-05-02 1994-11-04 Pasteur Institut Souches recombinantes immunogenes de b. anthracis - compositions immunogenes les contenant.
US5840312A (en) * 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
AU672372B2 (en) * 1991-11-08 1996-10-03 Pharmacia & Upjohn Company Feline leukemia virus vaccines
CZ286632B6 (cs) 1992-09-29 2000-05-17 Inhale Therapeutic Systems Farmaceutický prostředek
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
ATE264096T1 (de) 1994-03-07 2004-04-15 Nektar Therapeutics Verfahren und mittel zur verabreichung von insulin über die lunge
CA2212682A1 (en) * 1995-02-10 1996-08-15 Worcester Foundation For Experimental Biology, Inc. Delivery of exogenous compounds
US6013506A (en) * 1995-06-05 2000-01-11 Wardley; Richard C. Feline leukemia virus vaccines
DE59507617D1 (de) * 1995-09-06 2000-02-17 Schablonentechnik Kufstein Ag Verfahren zum Herstellen einer Siebdruckschablone
US6723558B1 (en) 1996-01-23 2004-04-20 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
JP2005514393A (ja) 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485810T2 (de) * 1983-05-27 1992-12-10 Texas A & M University Syst Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
US4662514A (en) * 1983-11-01 1987-05-05 Charleswater Products, Inc. Electrically conductive polymeric tubes for static sensitive electronic devices
IL76082A (en) * 1984-08-22 1991-07-18 Us Health Molecular clones of the genome of htlv-iii and a process for the preparation thereof
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
KR930000189B1 (ko) * 1984-10-18 1993-01-11 앵스뛰띠 빠스뙤르 임파선증과 후천성 면역 결핍증 바이러스의 항원을 제조하는 방법 및 이 항원에 대한 항체의 생산 방법
GB8501473D0 (en) * 1985-01-21 1985-02-20 Pasteur Institut Cloned dna sequences
CA1341482C (en) * 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
AU600658B2 (en) * 1984-12-24 1990-08-23 Genentech Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
FI861626A7 (fi) * 1985-04-19 1986-10-20 Hoffmann La Roche Foervaervat immunbristsyndrom (aids) -relaterat viralt rekombinant hoeljeprotein samt ett testfoerfarande foer aids.
FR2586427B1 (fr) * 1985-08-20 1988-12-09 Pasteur Institut Sequences de nucleotides et de polypeptides issus du virus visna et leur application a des essais de diagnostic et a la production de compositions immunogenes

Also Published As

Publication number Publication date
CH676247A5 (enrdf_load_html_response) 1990-12-28
CN86106632A (zh) 1987-05-13
SE9102974L (sv) 1993-04-15
HU205780B (en) 1992-06-29
GB2181435A (en) 1987-04-23
SE9102976L (sv) 1993-04-15
IL80073A (en) 1995-01-24
SE9102975L (sv) 1993-04-15
ES2006941A6 (es) 1989-05-16
FI863848A7 (fi) 1987-03-26
SE8604007D0 (sv) 1986-09-23
YU46753B (sh) 1994-05-10
GB2181435B (en) 1990-01-10
GR862412B (en) 1987-01-23
IE59314B1 (en) 1994-02-09
PT83434B (pt) 1988-07-29
IL80073A0 (en) 1986-12-31
DK455486A (da) 1987-03-26
FR2587720B2 (enrdf_load_html_response) 1995-02-10
PT83434A (en) 1986-10-01
IE862525L (en) 1987-03-25
NO863803L (no) 1987-03-26
SE9102976D0 (sv) 1991-10-14
SE9102975D0 (sv) 1991-10-14
NZ217645A (en) 1991-11-26
NL8602422A (nl) 1987-04-16
DK455486D0 (da) 1986-09-24
IT8667730A0 (it) 1986-09-24
ES2002490A6 (es) 1988-08-16
CN1020752C (zh) 1993-05-19
DE3690508T1 (enrdf_load_html_response) 1988-06-23
NO863803D0 (no) 1986-09-24
FI863848L (fi) 1987-03-26
YU165486A (en) 1989-08-31
FR2587720A2 (fr) 1987-03-27
IT1195829B (it) 1988-10-27
SE9102974D0 (sv) 1991-10-14
MY103182A (en) 1993-05-29
ATA256786A (de) 1995-05-15
WO1987002038A1 (en) 1987-04-09
HUT42133A (en) 1987-06-29
FI863848A0 (fi) 1986-09-24
GB8622987D0 (en) 1986-10-29

Similar Documents

Publication Publication Date Title
SE8604007D0 (sv) Vaccin och immunoanalyser for forvervat immunbristsyndrom (aids)
Osterhaus et al. Induction of protective immune response in cats by vaccination with feline leukemia virus iscom.
NO169844C (no) Htlv-iii (env)-peptider
BG98523A (en) Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b
SE8701413L (sv) Expression och rening av en htlv-iii gag/env-gen protein
DE69333397D1 (de) Retro-, inverso-, und retro-inverso synthetische peptidanaloge
DK0610250T4 (da) Vaccine med porcint reproduktivt respiratorisk syndrom (PRRS) og diagnose heraf
BR1101088A (pt) Proteìna g do vìrus sincicial respiratório não glicosilada isolada e substancialmente pura
DK0584348T3 (da) Genetisk vaccine mod immundefektvirusser
EA200300336A1 (ru) Пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
DK614987D0 (da) Syntetiske htlv-iii peptider, praeparater og anvendelser deraf
EA200300335A1 (ru) Регуляторные и вспомогательные пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
Merza et al. Characterization of purified gp 51 from bovine leukemia virus integrated into iscom: physicochemical properties and serum antibody response to the integrated gp 51
DK46988D0 (da) Fremgangsmaade til fremstilling af katteleukaemivirusantigener og anvendelsen heraf
SE8701765D0 (sv) Analysis method and means therefor
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
ES2095258T3 (es) Nuevo virus de la enfermedad de la bolsa infecciosa.
HÖGLUND et al. Characterization of immunostimulating complexes (ISCOMs) of HIV-1
SE9202934D0 (sv) Vacciner mot melanom
ATE122236T1 (de) Vorläufer des hüllenglykoproteins des hiv-2 retrovirus und verwandte antigene.
Osterhaus et al. Toward vaccination against feline leukemia virus and feline immunodeficiency virus infections

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 8604007-8

Format of ref document f/p: F